Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia. - Moore CG; Chyong DI; Daver N; Aubrey BJ; Marx KR; Takahashi K; Abaza Y; Smith CC; Amrein PC; Hock H; Hobbs G; Narayan R; et al. (British journal of haematology, 2026)